Atacicept in primary IgA nephropathy: efficacy, biomarker modulation, and safety - a systematic review and meta-analysis
Authors: Abdulrahman Alkhamis , Khalid Aldawsari , Abdulrahman Aljaafar , Hammad Altemani , Turki Alhazmi , Naif Abdullah Alrommani , Mohammad Allumaylim , Musaad Alsulaim , Sami Alsweed , Jaber Abdullah Alshahrani
Abstract
Background: IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and kidney failure worldwide, with limited disease specific therapies available. Atacicept, a dual inhibitor of B cell activating factor and a proliferation inducing ligand, targets key immunological pathways involved in disease pathogenesis. This systematic review and meta-analysis evaluated the efficacy and safety of atacicept in patients with IgAN.
Methodology: A systematic search of PubMed, Google Scholar, ScienceDirect, Cochrane Library, and ClinicalTrials.gov was conducted from inception to March 2026. Randomized, double blind, placebo controlled trials in adults with biopsy confirmed IgA nephropathy were included. Data was pooled using a random effects model. Continuous outcomes were analyzed as mean differences (MD) and dichotomous outcomes as risk ratios (RR), each with 95% confidence intervals. Heterogeneity was assessed using the I² statistic. Subgroup analyses were performed by atacicept dose (25 mg, 75 mg, and 150 mg).
Results: In adults with primary IgAN, three randomized controlled trials (560 participants total) evaluated atacicept against placebo. Atacicept significantly reduced urine protein to creatinine ratio (UPCR) at week 24 (MD −29.04%; p < 0.0001) and week 36 (MD −38.61%; p < 0.0001), with no heterogeneity. Estimated glomerular filtration rate (eGFR) improved significantly at week 36 (MD +8.59 mL/min/1.73 m²; p = 0.002). Galactose deficient IgA1 (Gd-IgA1) and total immunoglobulin levels were significantly suppressed. The overall adverse event profile was comparable to placebo across all safety endpoints.
Conclusion: Atacicept was associated with improvements in proteinuria, eGFR, and immunological biomarkers compared with placebo, while demonstrating a safety profile comparable to placebo. Because proteinuria and eGFR are surrogate renal endpoints, these findings should be interpreted as evidence of short term biological activity rather than established long term renal benefit. Larger, long term trials evaluating clinically meaningful renal outcomes are needed to define the role of atacicept in clinical practice.
Keywords: IgA nephropathy, atacicept, proteinuria, BAFF/APRIL inhibition, meta-analysis.
Pubmed Style
Abdulrahman Alkhamis, Khalid Aldawsari, Abdulrahman Aljaafar, Hammad Altemani, Turki Alhazmi, Naif Abdullah Alrommani, Mohammad Allumaylim, Musaad Alsulaim, Sami Alsweed, Jaber Abdullah Alshahrani. Atacicept in primary IgA nephropathy: efficacy, biomarker modulation, and safety - a systematic review and meta-analysis. AMEM. 2026; 04 (November 2026): -. doi:10.24911/amem.15-3235
Publication History
Received: October 13, 2026
Revised: October 15, 2026
Accepted: October 19, 2026
Published: November 04, 2026
Authors
Abdulrahman Alkhamis
College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Khalid Aldawsari
College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Abdulrahman Aljaafar
College of Medicine, King Abdulaziz University, Jedda, Saudi Arabia.
Hammad Altemani
College of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Turki Alhazmi
College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Naif Abdullah Alrommani
College of Medicine, Sulaiman Alrajhi University, Al-Bukairiyah, Saudi Arabia.
Mohammad Allumaylim
College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Musaad Alsulaim
College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Sami Alsweed
College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Jaber Abdullah Alshahrani
Family Medicine Department, Armed Forces Hospital Southern Region, Ministry of Defense Health Services, Khamis Mushait, Saudi Arabia.